Antithrombotic Therapy for Vascular Bypass Grafts

Introduction to Antithrombotic Regimens

• The American College of Chest Physicians recommends single antiplatelet therapy with either aspirin (75-100 mg daily) or clopidogrel (75 mg daily) as the optimal antithrombotic regimen for long-term management of patients undergoing redo vascular bypass grafts with a history of failed bypass 1
• Aspirin may be continued through the perioperative period at low dose (75-100 mg daily), according to the American College of Chest Physicians 1
• Initiation of aspirin 75-100 mg daily within 6 hours after surgery is recommended, if possible, by the American College of Chest Physicians 1
• If postoperative bleeding prevents early administration, the American College of Chest Physicians suggests starting aspirin as soon as bleeding risk stabilizes 1

Antiplatelet Therapy Options

• Single antiplatelet therapy is preferred over dual antiplatelet therapy for peripheral bypass grafts, with options including aspirin 75-100 mg daily (first-line option) and clopidogrel 75 mg daily (alternative for aspirin-intolerant patients), as recommended by the American College of Chest Physicians 1
• For below-knee prosthetic grafts, the American College of Chest Physicians suggests considering clopidogrel 75 mg daily plus aspirin 75-100 mg daily for the first 12 months, then single antiplatelet therapy thereafter 1
• Aspirin (75-100 mg daily) is recommended as a preferred option due to its efficacy and safety profile, with a lower risk of bleeding compared to higher doses 1
• Clopidogrel (75 mg daily) can be used as an alternative to aspirin, especially in patients with aspirin allergy or intolerance, with a similar efficacy and safety profile 1

Special Considerations

• For patients with recent acute coronary syndrome (<12 months), the American College of Cardiology recommends considering continuing P2Y12 inhibitor (preferably clopidogrel) plus oral anticoagulation if indicated 2
• After 12 months, the American College of Cardiology suggests transitioning to single antiplatelet therapy 2
• The American College of Chest Physicians advises avoiding high-dose aspirin (>100 mg daily), as it increases bleeding risk without additional antithrombotic benefit 1
• The American College of Chest Physicians also recommends avoiding routine dual antiplatelet therapy for all patients, as evidence supports this approach only for specific subgroups (below-knee prosthetic grafts) 1
• The combination of antiplatelet therapy with oral anticoagulation significantly increases bleeding risk, particularly in patients with atrial fibrillation or other conditions requiring anticoagulation, and should be managed with caution 3
• Single antiplatelet therapy (preferably clopidogrel) plus oral anticoagulation for 6 months may be considered, followed by oral anticoagulation alone, in patients requiring oral anticoagulation, such as those with atrial fibrillation, to balance the risk of thrombotic events and bleeding 3

Dual Antiplatelet Therapy (DAPT) Duration

• The following table summarizes the recommended duration of DAPT based on patient risk profile:

• Extended DAPT (18-48 months) compared to 6-12 months shows decreased MI (OR: 0.67; 95% CI: 0.47 to 0.95) and stent thrombosis (OR: 0.45; 95% CI: 0.24 to 0.74), but increased major hemorrhage (OR: 1.58; 95% CI: 1.20 to 2.09), as noted by the American Heart Association and the American College of Cardiology with a moderate strength of evidence 4, 5
• Patients with high bleeding risk should be considered for adjusted DAPT duration, including those with advanced age, oral anticoagulant use, history of bleeding, coagulopathy, or end-stage renal failure, while patients with low bleeding risk and high thrombotic risk factors should be considered for extended DAPT duration, as recommended by the American College of Cardiology with a moderate strength of evidence 6, 7, 8

Management of Antithrombotic Therapy

• Aspirin 81mg daily should be started with a loading dose of 81-325 mg before the procedure and continued indefinitely, with low-dose aspirin (81 mg) preferred over higher doses to reduce bleeding risk, as recommended by Circulation with a high strength of evidence 9, 10, 7, 11
• Clopidogrel should be started with a 600 mg loading dose followed by 75 mg daily maintenance, while Prasugrel should be started with a 60 mg loading dose followed by 10 mg daily for ACS patients, but should not be used in patients with a prior history of stroke or transient ischemic attack, as recommended by the American College of Cardiology with a moderate strength of evidence 10, 9, 7
• Ticagrelor should be started with a 180 mg loading dose followed by 90 mg twice daily for ACS patients, and is a reasonable choice for maintenance P2Y12 inhibitor therapy in preference to clopidogrel for ACS patients, as suggested by the American College of Cardiology with a moderate strength of evidence 10, 12, 7
• A proton pump inhibitor is recommended in patients at increased risk of gastrointestinal bleeding for the duration of combined antithrombotic therapy, and aspirin 75-100 mg daily lifelong should be continued after completing DAPT, as suggested by the European Society of Cardiology with a moderate strength of evidence 13, 7
• Premature discontinuation of DAPT increases the risk of stent thrombosis, myocardial infarction, and death, and should be avoided, with elective procedures recommended to be delayed until completion of 12 months of DAPT, according to the American College of Cardiology and the American Heart Association with a high strength of evidence 14, 15